Vol. 3 No. 2 (2026)

Review Articles

Epstein-Barr Virus Participates in the Development and Progression of Nasopharyngeal Carcinoma and its Application in Traditional Chinese and Western Medicine Integrated Treatment

Published 2026-03-31

  • Lin Chen
    • ,
  • Faqing Tang

Lin Chen
Hunan Key Laboratory of Oncotarget Gene and Clinical Laboratory, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/ Hunan Cancer Hospital, Changsha 410013, China

Faqing Tang
The First Clinical College of Traditional Chinese Medicine of Hunan University of Chinese Medicine, and Hunan Cancer Hospital, Changsha, 410007, China

Abstract

Nasopharyngeal carcinoma (NPC) is a epithelial tumor from the nasopharynx. Its pathogenesis is closely related to Epstein-Barr virus (EBV) infection, the patients account for over 95% of global NPC incidence. NPC is a highly malignant tumor, with over 70% of patients diagnosed at an intermediate or advanced stage. Over 90% of those diagnosed with undifferentiated NPC are infected with EBV. Currently, radiotherapy alone and concurrent chemoradiotherapy are the main treatment options for NPC. Early-stage NPC is primarily treated with radical radiotherapy, appropriately combined with chemotherapy, while locally advanced NPC is treated with concurrent chemoradiotherapy. However, long-term radiotherapy and chemotherapy can be difficult for NPC patients and can cause corresponding toxic side effects. Therefore, tumor immunotherapy is a promising treatment method for NPC, including vaccination, adoptive cell therapy, and immune checkpoint blockade. In addition, traditional Chinese medicine treatment can improve the immune status of NPC patients, reduce the toxic side effects of radiotherapy and chemotherapy, and improve survival time and quality of life. Therefore, the traditional Chinese and Western medicine treatment for NPC patients has shown remarkable efficacy; this also suggests that the traditional Chinese and Western medicine treatment of NPC has broad development prospects. Herin, we summarize mechanisms of EBV involved in NPC, and mainly elaborate the traditional Chinese and Western medicine treatment targeted EBV for NPC patients. This article provides some insights for future related research.

Keywords

Epstein-Barr virus, Nasopharyngeal carcinoma, Traditional Chinese medicine, Integrated treatment of traditional Chinese

PDF

References

  1. Young LS, Yap LF, Murray PG. Epstein-Barr virus: more than 50 years old and still providing surprises [J] .Nat Rev Cancer , 2016 , 16(12):789-802. https://doi.org/10.1038/nrc.2016.92
  2. Duan X, Chen H, Zhou X, et al. EBV Infection in Epithelial Malignancies Induces Resistance to Antitumor Natural Killer Cells via F3-Mediated Platelet Aggregation [J] . Cancer Res, 2022, 82(6):1070-1083. https://doi.org/10.1158/0008-5472.CAN-21-2292
  3. Huang YH, Zhang CZ, Huang QS, et al. Clinicopathologic features, tumorimmune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma [J] .J Hepatol , 2021 , 74(4):838-849. https://doi.org/10.1016/j.jhep.2020.10.037
  4. Ko YH. EBV and human cancer [J] .Exp Mol Med , 2015 , 47(1):e130. https://doi.org/10.1038/emm.2014.109
  5. Zheng X, Wang R, Zhang X, et al. A deep learning model and human-machine fusion for prediction of EBV-associated gastric cancer from histopathology [J] .Nat Commun , 2022 , 13(1):2790. https://doi.org/10.1038/s41467-022-30459-5
  6. Kanda T, Yajima M, Ikuta K. Epstein-Barr virus strain variation and cancer [J] .Cancer Sci , 2019 , 110(4):1132-1139. https://doi.org/10.1111/cas.13954
  7. Jha HC, Pei Y, Robertson ES. Epstein-Barr Virus: Diseases Linked to Infection and Transformation [J] . Front Microbiol , 2016 , 7:1602. https://doi.org/10.3389/fmicb.2016.01602
  8. Xiang T, Lin YX, Ma W, et al. Vasculogenic mimicry formation in EBV-associated epithelial malignancies [J] . Nat Commun , 2018 , 9(1):5009. https://doi.org/10.1038/s41467-018-07308-5
  9. Leong MML, Lung ML. The Impact of Epstein-Barr Virus Infection on Epigenetic Regulation of Host Cell Gene Expression in Epithelial and Lymphocytic Malignancies [J] .Front Oncol , 2021 , 11:629780. https://doi.org/10.3389/fonc.2021.629780
  10. Su ZY, Siak PY, Lwin YY, et al. Epidemiology of nasopharyngeal carcinoma: current insights and future outlook [J]. Cancer Metastasis Rev , 2024 , 43(3):919-939. https://doi.org/10.1007/s10555-024-10176-9
  11. Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma [J]. Lancet , 2019 , 394(10192):64-80. https://doi.org/10.1016/S0140-6736(19)30956-0
  12. Xie Z, Li W, Ai J, et al. C2orf40 inhibits metastasis and regulates chemo-resistance and radio-resistance of nasopharyngeal carcinoma cells by influencing cell cycle and activating the PI3K/AKT/mTOR signaling pathway [J] .J Transl Med , 2022, 20(1):264. https://doi.org/10.1186/s12967-022-03446-z
  13. Jiromaru R, Nakagawa T, Yasumatsu R. Advanced Nasopharyngeal Carcinoma: Currentand and Emerging Treatment Options [J] . Cancer Manag Res , 2022 , 14:2681-2689. https://doi.org/10.2147/CMAR.S341472
  14. Zhang L, Chen QY, Liu H, et al. Emerging treatment options for nasopharyngeal carcinoma [J] . Drug Des Devel Ther , 2013 , 7:37-52. https://doi.org/10.2147/DDDT.S30753
  15. Spratt DE, Lee N. Current and emerging treatment options for nasopharyngeal carcinoma [J] . Onco Targets Ther , 2012 , 5:297-308. https://doi.org/10.2147/OTT.S28032
  16. Sidaway P. Chemoradiotherapy improves NPC outcomes [J]. Nat Rev Clin Oncol , 2020 , 17(10):592. https://doi.org/10.1038/s41571-020-0424-9
  17. Chen YP, Ismaila N, Chua MLK, et al. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCOand ASCO Guideline [J] .J Clin Oncol , 2021 , 39(7):840-859. https://doi.org/10.1200/JCO.20.03237
  18. Li WF, Chen NY, Zhang N, et al. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial [J] . Int J Cancer , 2019 , 145(1):295-305. https://doi.org/10.1002/ijc.32099
  19. Tang QN, Liu LT, Qi B, et al. Effect of Concurrent Chemoradiotherapy With Nedaplatin vs Cisplatin on the Long-term Outcomes of Survival and Toxic Effects Among Patients With Stage II to IVB Nasopharyngeal Carcinoma: A 5-Year Follow-up Secondary Analysis of a Randomized Clinical Trial [J] .JAMA Netw Open , 2021 , 4(12):e2138470. https://doi.org/10.1001/jamanetworkopen.2021.38470
  20. Yang Q, Cao SM, Guo L, et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomized controlled trial [J] . Eur J Cancer , 2019 , 119:87-96. https://doi.org/10.1016/j.ejca.2019.07.007
  21. Le QT, Colevas AD, O'Sullivan B, et al. Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy [J] .J Natl Cancer Inst , 2019 , 111(7):655-663. https://doi.org/10.1093/jnci/djz044
  22. Chen YP, Lv JW, Mao YP, et al. Unraveling tumor microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses [J] .Mol Cancer , 2021 , 20(1):14. https://doi.org/10.1186/s12943-020-01292-5
  23. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from burkitt's lymphoma [J] .Lancet , 1964 , 1(7335):702-703. https://doi.org/10.1016/s0140-6736(64)91524-7
  24. Esau D. Viral causes of lymphoma: The history of Epstein-Barr virus and human T-lymphotropic virus 1 [J] . Virol (Auckl) , 2017, 8:1178122X17731772. https://doi.org/10.1177/1178122X17731772
  25. Tillman H, Vogel P, Rogers T, et al. Spectrum of Posttransplant Lymphoproliferations in NSG Mice and Their Association With EBV Infection AfterEngraftment of Pediatric Solid Tumors [J] . Vet Pathol , 2020 , 57(3):445-456. https://doi.org/10.1177/0300985820913265
  26. Cohen JI, Mocarski ES, Raab-Traub N, et al. The need and challenges for development of an Epstein-Barr virus vaccine [J] .Vaccine , 2013;31(02):B194-B196. https://doi.org/10.1016/j.vaccine.2012.09.041
  27. Arvin A, Campadelli-Fiume G, Mocarski E, et al. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis [M]. Cambridge: Cambridge University Press , 2007. PMID: 21348071. ISBN-13: 9780521827140
  28. Miller G, El-Guindy A, Countryman J, et al. Lytic cycle switches of oncogenic human gammaherpesviruses [J] . Adv Cancer Res, 2007 , 97:81-109. https://doi.org/10.1016/S0065-230X(06)97004-3
  29. Murata T, Tsurumi T. Switching of EBV cycles between latent and lytic states [J] .Rev Med Virol , 2014 , 24(3):142-153. https://doi.org/10.1002/rmv.1780
  30. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas [J] .N Engl J Med , 2004 , 350(13):1328-1337. https://doi.org/10.1056/NEJMra032015
  31. Tse E, Kwong YL. Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target [J] .Exp Mol Med , 2015 , 47(1):e136. https://doi.org/10.1038/emm.2014.102
  32. Heslop HE. Sensitizing Burkitt lymphoma to EBV-CTLs [J] . Blood , 2020 , 135(21):1822-1823. https://doi.org/10.1182/blood.2020005492
  33. Hutt-Fletcher LM. Epstein-Barr virus replicating in epithelial cells [J] .Proc Natl Acad Sci USA , 2014 , 111(46):16242-16243. https://doi.org/10.1073/pnas.1418974111
  34. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells [J] . Nature , 1985 , 313(6005):812-815. https://doi.org/10.1038/313812a0
  35. Cao JY, Mansouri S, Frappier L. Changes in the nasopharyngeal carcinoma nuclear proteome induced by the EBNA1 protein of Epstein-Barr virus reveal potential roles for EBNA1 in metastasis and oxidative stress responses [J] .J Virol , 2012 , 86(1):382-394. https://doi.org/10.1128/JVI.05648-11
  36. Soldan SS, Anderson EM, Frase DM, et al. EBNA1 inhibitors have potent and selective antitumor activity in xenograft models of Epstein-Barr virus-associated gastric cancer [J] . Gastric Cancer , 2021 , 24(5):1076-1088. https://doi.org/10.1007/s10120-021-01193-6
  37. Uchida J, Yasui T, Takaoka-Shichijo Y, et al. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses [J] .Science , 1999 , 286(5438):300-303. https://doi.org/10.1126/science.286.5438.300
  38. Cheerathodi MR, Meckes DG Jr. The Epstein-Barr virus LMP1 interactome: biological implications and therapeutic targets [J] . Future Virol , 2018 , 13(12):863-887. https://doi.org/10.2217/fvl-2018-0120
  39. Dawson CW, Tramountanis G, Eliopoulos AG, et al. Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling [J] . J Biol Chem , 2003 , 278(6):3694-3704. https://doi.org/10.1074/jbc.M209840200
  40. Sakamoto Y, Mariya Y, Kubo K. Quantification of Epstein-Barr virus DNA is helpful for evaluation of chronic active Epstein-Barr virus infection [J] .Tohoku J Exp Med , 2012 , 227(4):307-311. https://doi.org/10.1620/tjem.227.307
  41. Pietersma F, Piriou E, van Baarle D. Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients [J] .Leuk Lymphoma , 2008 , 49(6):1028-1041. https://doi.org/10.1080/10428190801911662
  42. Sebelin-Wulf K, Nguyen TD, Oertel S, et al. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD [J] . Transpl Immunol , 2007 , 17(3):203-210. https://doi.org/10.1016/j.trim.2006.10.006
  43. Kim HJ, Ko YH, Kim JE, et al. Epstein-Barr Virus-Associated Lymphoproliferative Disorders: Review and Update on 2016 WHO Classification [J] .J Pathol Transl Med , 2017 , 51(4):352-358. https://doi.org/10.4132/jptm.2017.03.15
  44. Bar-Or A, Pender MP, Khanna R, et al. Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies [J]. Trends Mol Med , 2021 , 27(4):410-411. https://doi.org/10.1016/j.molmed.2021.01.004
  45. Khan G, Fitzmaurice C, Naghavi M, et al. Global and regional incidence, mortality and disability-adjusted life-years for Epstein-Barr virus-attributable malignancies, 1990-2017 [J] .BMJ Open , 2020 , 10(8):e037505. https://doi.org/10.1136/bmjopen-2020-037505
  46. Taylor GS, Blackbourn DJ. Infectious agents in human cancers: lessons in Immunity and immunomodulation from gammaherpesviruses EBV and KSHV [J] . Cancer Lett , 2011 , 305(2):263-278. https://doi.org/10.1016/j.canlet.2010.08.019
  47. Raghupathy R, Hui EP, Chan AT. Epstein-Barr virus as a paradigm in nasopharyngeal cancer: from lab to clinic [J] .Am Soc Clin Oncol Educ Book , 2014 : 149-153. https://doi.org/10.14694/EdBook_AM.2014.34.149
  48. Xu L, Huang TJ, Hu H, et al. The developmental transcription factor IRF6 attenuates ABCG2 gene expression and distinctively reverses stemness phenotype in nasopharyngeal carcinoma [J] . Cancer Lett , 2018 , 431:230-243. https://doi.org/10.1016/j.canlet.2017.10.016
  49. Lo AK, Dawson CW, Lung HL, et al. The Role of EBV-Encoded LMP1 in the NPC Tumor Microenvironment: From Function to Therapy [J] . Front Oncol , 2021 , 11:640207. https://doi.org/10.3389/fonc.2021.640207
  50. Lin DC, Meng X, Hazawa M, et al. The genomic landscape of nasopharyngeal carcinoma [J] .Nat Genet , 2014 , 46(8):866-871. https://doi.org/10.1038/ng.3006
  51. Bruce JP, To KF, Lui VWY, et al. Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-κB activation and immune escape [J] .Nat Commun , 2022 , 13(1):4353. https://doi.org/10.1038/s41467-022-32156-9
  52. Liu MT, Chang YT, Chen SC, et al. Epstein-Barr virus latent membrane protein 1 represses p53-mediated DNA repair and transcriptional activity [J] . Oncogene , 2005 , 24(16):2635-2646. https://doi.org/10.1038/sj.onc.1208319
  53. Bentz GL, Liu R, Hahn AM, et al. Epstein-Barr virus BRLF1 inhibits transcription of IRF3 and IRF7 and suppresses induction of interferon-beta [J] . Virology , 2010 , 402(1):121-128. https://doi.org/10.1016/j.virol.2010.03.014
  54. Nanbo A, Inoue K, Adachi-Takasawa K, et al. Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma [J] . EMBO J , 2002 , 21(5):954-965. https://doi.org/10.1093/emboj/21.5.954
  55. Gourzones C, Barjon C, Busson P. Host-tumor interactions in nasopharyngeal carcinomas [J] . Semin Cancer Biol , 2012 , 22(2):127-136. https://doi.org/10.1016/j.semcancer.2012.01.002
  56. Whiteside TL. RE: Effect of Nasopharyngeal Carcinoma-Derived Exosomeson Human Regulatory T Cells [J] .J Natl Cancer Inst , 2015 , 107(12):djv276. https://doi.org/10.1093/jnci/djv276
  57. Shah KM, Stewart SE, Wei W, et al. The EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the actions of interferon by targeting interferon receptors for degradation [J]. Oncogene , 2009 , 28(44):3903-3914. https://doi.org/10.1038/onc.2009.249
  58. Raab-Traub N. Nasopharyngeal carcinoma: an evolving role for the Epstein-Barr virus [J] . Curr. Top. Microbiol. Immunol . 2015, 390:339-363. https://doi.org/10.1007/978-3-319-22822-8_14
  59. Nachmani D, Stern-Ginossar N, Sarid R, et al. Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells [J] . Cell Host Microbe , 2009 , 5(4):376-385. https://doi.org/10.1016/j.chom.2009.03.003
  60. Peng G, Wang T, Yang KY, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma [J] . Radiother Oncol , 2012 , 104(3):286-293. https://doi.org/10.1016/j.radonc.2012.08.013
  61. Chen QY, Wen YF, Guo L, et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial [J] . J Natl Cancer Inst , 2011 , 103(23):1761-1770. https://doi.org/10.1093/jnci/djr432
  62. Li XY, Chen QY, Sun XS, et al. Ten-year outcomes of survival and toxicity for a phase III randomized trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma [J] . Eur J Cancer , 2019 , 110:24-31. https://doi.org/10.1016/j.ejca.2018.10.020
  63. Su SF, Han F, Zhao C, et al. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone [J] .Int J Radiat Oncol Biol Phys, 2012 , 82(1):327-333. https://doi.org/10.1016/j.ijrobp.2010.09.011
  64. Luo S, Zhao L, Wang J, et al. Clinical outcomes for early-stage nasopharyngeal carcinoma with predominantly WHO II histology treated by intensity-modulated radiation therapy with or without chemotherapy in nonendemic region of China [J] .Head Neck , 2014 , 36(6):841-847. https://doi.org/10.1002/hed.23386
  65. Guo Q, Lu T, Lin S, et al. Long-term survival of nasopharyngeal carcinoma patients with Stage II in intensity-modulated radiation therapy era [J] .Jpn J Clin Oncol , 2016 , 46(3):241-247. https://doi.org/10.1093/jjco/hyv192
  66. Huang X, Chen X, Zhao C, et al. Adding Concurrent Chemotherapy to Intensity-Modulated Radiotherapy Does Not Improve Treatment Outcomes forStage II Nasopharyngeal Carcinoma: A Phase 2 Multicenter Clinical Trial [J] . Front Oncol , 2020 , 10:1314. https://doi.org/10.3389/fonc.2020.01314
  67. Tang LL, Guo R, Zhang N, et al. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial [J] .JAMA , 2022 , 328(8):728-736. https://doi.org/10.1001/jama.2022.13997
  68. Lang J, Hu C, Lu T, et al. Chinese expert consensus on diagnosis and treatment of nasopharyngeal carcinoma: evidence from current practice and future perspectives [J] .Cancer Manag Res , 2019 , 11:6365-6376. https://doi.org/10.2147/CMAR.S197544
  69. Chen YP, Ismaila N, Chua MLK, et al. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline [J] .J Clin Oncol , 2021 , 39(7):840-859. https://doi.org/10.1200/JCO.20.03237
  70. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099 [J] .J Clin Oncol , 2023 , 41(24):3965-3972. https://doi.org/10.1200/JCO.22.02764
  71. Lee AW, Tung SY, Chua DT, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma [J] . J Natl Cancer Inst , 2010 , 102(15):1188-1198. https://doi.org/10.1093/jnci/djq258
  72. Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety [J] .J ClinOncol , 2005 , 23(27):6730-6738. https://doi.org/10.1200/JCO.2005.16.790
  73. Chan AT, Teo PM, Ngan RK, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial [J] .J Clin Oncol , 2002 , 20(8):2038-2044. https://doi.org/10.1200/JCO.2002.08.149
  74. Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma [J] . J Natl Cancer Inst , 2005 , 97(7):536-539. https://doi.org/10.1093/jnci/dji084
  75. Xia WX, Lv X, Liang H, et al. A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer [J] . Clin Cancer Res , 2021 ,27(15):4186-4194. https://doi.org/10.1158/1078-0432.CCR-20-4532
  76. You R, Sun R, Hua YJ, et al. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma [J] . Int J Cancer , 2017 , 141(6):1265-1276. https://doi.org/10.1002/ijc.30819
  77. Liu LT, Liu H, Huang Y, et al. Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomized, controlled, phase 3 trial [J] .Lancet Oncol , 2023 , 24(7):798-810. https://doi.org/10.1016/S1470-2045(23)00232-2
  78. Blanchard P, Lee A, Marguet S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis [J] . Lancet Oncol , 2015 , 16(6):645-655. https://doi.org/10.1016/S1470-2045(15)70126-9
  79. Ribassin-Majed L, Marguet S, Lee AWM, et al. What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis [J] .J Clin Oncol, 2017 , 35(5):498-505. https://doi.org/10.1200/JCO.2016.67.4119
  80. Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma [J] .N Engl J Med , 2019 , 381(12):1124-1135. https://doi.org/10.1056/NEJMoa1905287
  81. Zhang Y, Chen L, Hu GQ, et al. Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial [J] .J Clin Oncol , 2022 , 40(22):2420-2425. https://doi.org/10.1200/JCO.22.00327
  82. Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomized controlled trial [J] . Lancet Oncol , 2016 , 17(11):1509-1520. https://doi.org/10.1016/S1470-2045(16)30410-7
  83. Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomized controlled trial [J] . Lancet Oncol , 2012 , 13(2):163-171. https://doi.org/10.1016/S1470-2045(11)70320-5
  84. Chen L, Hu CS, Chen XZ, et al. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomized controlled trial [J] . Eur J Cancer , 2017 , 75:150-158. https://doi.org/10.1016/j.ejca.2017.01.002
  85. Chan ATC, Hui EP, Ngan RKC, et al. Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial [J] .J Clin Oncol , 2018 , 10:JCO2018777847. https://doi.org/10.1200/JCO.2018.77.7847
  86. Chen YP, Liu X, Zhou Q, et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial [J] . Lancet , 2021 , 398(10297):303-313. https://doi.org/10.1016/S0140-6736(21)01123-5
  87. Miao J, Wang L, Tan SH, et al. Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Clinical Trial [J]. JAMA Oncol ,2022,8(12):1776-1785. https://doi.org/10.1001/jamaoncol.2022.4656
  88. Cui X, Snapper CM. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases [J] . Front Immunol , 2021 , 12:734471. https://doi.org/10.3389/fimmu.2021.734471
  89. Liang R, Yang L, Zhu X. Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma [J] . Cancer Control , 2021 , 28:1073274821989301. https://doi.org/10.1177/1073274821989301
  90. Louis CU, Straathof K, Bollard CM, et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma [J]. J Immunother, 2010, 33(9):983-990. https://doi.org/10.1097/CJI.0b013e3181f3cbf4
  91. Jiang Zhichao. Pathological significance of CD4+CD25+ T regulatory cells in immune tolerance in the microenvironment of mid-to-late stage nasopharyngeal carcinoma and the reversal effect of Yiqi Jiedu formula [D]. Hunan University of Traditional Chinese Medicine, 2013.
  92. Zhang Bei, Wang Taoli, Huang Yuanyuan, et al. Study on the correlation between TCM syndrome type, clinical stage and EBV-DNA of newly diagnosed nasopharyngeal carcinoma[J]. Chinese Journal of Integrated Traditional and Western Medicine Otorhinolaryngology, 2011, 19(06):404-407. https://doi.org/10.3969/j.issn.1007-4856.2011.06.009
  93. Li Lulu. A study on the correlation between TCM syndrome types and T cell subsets in nasopharyngeal carcinoma [D]. Southwest Medical University , 2010. https://doi.org/10.7666/d.y1785191
  94. Mao CG, Tao ZZ, Wan LJ, et al. The efficacy of traditional Chinese Medicine as an adjunctive therapy in nasopharyngeal carcinoma: a systematic review and meta-analysis [J] .J BUON , 2014 , 19(2):540-548. PMID: 24965419.ISSN: 1107-0625, online ISSN: 2241-6293
  95. Gao Bingzong. Study on the effects of Qingre Liyan Decoction on acute oropharyngeal mucosal reaction and immune function induced by radiotherapy for nasopharyngeal carcinoma [J]. Chinese Medical Science, 2024, 14(04):67-70. https://doi.org/10.20116/j.issn2095-0616.2024.04.16
  96. Wang Bingsheng, Liu Xiufang, Wang Tao, et al. Study on the prevention and treatment of acute radiation injury by a formula for promoting blood circulation, replenishing qi and nourishing yin [J]. Chinese Journal of Integrated Traditional and Western Medicine, 2000, 20(03): 180-182. https://doi.org/10.3321/j.issn:1003-5370.2000.03.007